



ASX ANNOUNCEMENT

Lumos Diagnostics Signs Second ANZ Distribution Agreement for FebriDx®

MELBOURNE, Australia (9 September 2025) – Lumos Diagnostics Holdings Ltd (ASX: LDX, “Lumos” or the “Company”) a leader in rapid, point-of-care diagnostic technologies is pleased to announce the signing of a second distribution agreement for its flagship test, FebriDx®, in Australia and New Zealand. The new partnership with healthcare distributor Amtech (part of YesGroup) complements Lumos’ existing agreement with Henry Schein.

YesGroup is a major Australasian medical and safety supplies alliance, that brings together two trusted brands, Yes Medical, and Amtech Medical. The group serves healthcare and allied health markets across both countries and traces its foundations back to separate Australian and New Zealand companies founded in 1999 and 2004, respectively. Today, YesGroup employs over 150 team members and offers a portfolio with more than 25,000 product lines across multiple brands.

FebriDx® is a rapid, point-of-care test that helps healthcare professionals differentiate between bacterial and viral acute respiratory infections in around 10 minutes, supporting more informed clinical decision-making and potentially reducing unnecessary antibiotic prescribing.

“YesGroup are proud to partner with Lumos Diagnostics to bring FebriDx® to more clinicians across Australia and New Zealand. At YesGroup, our focus is to enable healthcare to perform better by providing professionals with innovative, evidence-based solutions that improve patient care and outcomes.

With FebriDx®, clinicians gain access to a rapid, reliable tool that supports smarter prescribing decisions and helps reduce the impact of antimicrobial resistance in our communities. This partnership is an important step in strengthening frontline care and continuing our commitment to deliver trusted products to healthcare providers throughout the region,” commented, Craig Anderson, CEO of YesGroup.

Commenting on the announcement, Doug Ward, CEO of Lumos Diagnostics said: *“We are delighted to expand FebriDx® distribution in Australia and New Zealand through this new partnership with YesGroup. With their reach and long-standing presence in the local healthcare market, alongside our existing agreement with Henry Schein, we are well positioned to make FebriDx® more widely accessible to clinicians.”*

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:

Haley Chartres – Australia
HACK Director
haley@hck.digital
+61 423 139 163

Investor Contact:

George Kopsiaftis
IR Specialist, IR Department
ir@lumosdiagnostics.com
+61 409 392 687

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Suite 2, Level 11
385 Bourke Street
Melbourne VIC 3000
info@lumosdiagnostics.com
+61 3 9087 1598